Image
Solid Biosciences has announced that the FDA has allowed the high-dose group to be included in the IGNITE DMD trial. However the trial remains on hold because of a potential safety concern. The first trial participant had a reaction to the gene therapy, though this was resolved with medical treatment. He is now reported to be doing well.
For more information, read Solid's community letter and press release.
To find out more about the latest research in Duchenne muscular dystrophy, please contact our Research team at research@musculardystrophyuk.org